Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing SHP2-based combination therapy for KRAS-amplified cancer.

JCI insight - 8 Feb 2023

Li Tianxia, Kikuchi Osamu, Zhou Jin, Wang Yichen, Pokharel Babita, Bastl Klavdija, Gokhale Prafulla, Knott Aine, Zhang Yanxi, Doench John G, Ho Zandra V, Catenacci Daniel Vt, Bass Adam J

Abstract excerpt

Gastroesophageal adenocarcinomas (GEAs) harbor recurrent amplification of KRAS, leading to marked overexpression of WT KRAS protein. We previously demonstrated that SHP2 phosphatase, which acts to promote KRAS and downstream MAPK pathway activation, is a target in these tumors when combined with MEK inhibition. We hypothesized that SHP2 inhibitors may serve as a foundation for developing novel combination...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to PI3K/AKT/mTOR signaling in cancer

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Protein Tyrosine Phosphatases

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 36752207
DOI: 10.1172/jci.insight.152714
PMCID: PMC9977440

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing SHP2-based combination therapy for KRAS-amplified cancer.PMID 36752207Read ↗

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies.Semantic proximity Read ↗

KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.Semantic proximity Read ↗

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Semantic proximity Read ↗

SHP2 Inhibition Abrogates Adaptive Resistance to KRAS <sup>G12C</sup> -Inhibition and Remodels the Tumor Microenvironment of <i>KRAS</i> -Mutant TumorsSemantic proximity Read ↗

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.Semantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.Semantic proximity Read ↗

EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers.Semantic proximity Read ↗

Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic CancerSemantic proximity Read ↗

SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.